0001551986-23-000028.txt : 20230427 0001551986-23-000028.hdr.sgml : 20230427 20230427081746 ACCESSION NUMBER: 0001551986-23-000028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230426 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230427 DATE AS OF CHANGE: 20230427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: 9 METERS BIOPHARMA, INC. CENTRAL INDEX KEY: 0001551986 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273948465 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37797 FILM NUMBER: 23852067 BUSINESS ADDRESS: STREET 1: 4509 CREEDMOOR ROAD STREET 2: SUITE 201 CITY: RALEIGH STATE: NC ZIP: 27612 BUSINESS PHONE: 919-275-1933 MAIL ADDRESS: STREET 1: 4509 CREEDMOOR ROAD STREET 2: SUITE 201 CITY: RALEIGH STATE: NC ZIP: 27612 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATE BIOPHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20180201 FORMER COMPANY: FORMER CONFORMED NAME: Monster Digital, Inc. DATE OF NAME CHANGE: 20150930 FORMER COMPANY: FORMER CONFORMED NAME: Tandon Digital, Inc. DATE OF NAME CHANGE: 20120611 8-K 1 nmtr-20230426.htm 8-K nmtr-20230426
0001551986FALSE00015519862023-04-262023-04-260001551986dei:FormerAddressMember2023-04-262023-04-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): April 26, 2023
 
 
 
9 Meters Biopharma, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 001-37797 27-3948465
(State or other jurisdiction of
incorporation or organization)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
4509 Creedmoor Road, Suite 600, Raleigh, NC 27612
(Address of principal executive offices) (Zip Code)
 
(919) 275-1933
(Registrant’s telephone number, include area code)
 
4509 Creedmoor Road, Suite 201, Raleigh, NC 27612
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock $0.0001 Par ValueNMTRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 



Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 1.01.Entry Into a Material Definitive Agreement.
The information related to the Forbearance Agreement (as defined below) set forth in Item 2.04 of this Current Report on Form 8-K is incorporated herein by reference.

Item 2.04.
Triggering Events that Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

As previously disclosed in the Current Report on Form 8-K filed on April 6, 2023 by 9 Meters Biopharma, Inc. (the “Company”), on March 31, 2023, the Company’s failure to maintain the minimum listing maintenance requirements of The Nasdaq Stock Market (“Nasdaq”) constitutes a default (the “Existing Default”) under the Company’s amended and restated senior secured convertible note, originally issued on July 15, 2022 to an institutional investor (the “Holder”), which was subsequently amended and restated on November 7, 2022, and further amended on January 12, 2023 (the “Note”).

On April 26, 2023, the Company entered into a forbearance agreement (the “Forbearance Agreement”) with the Holder, pursuant to which the Holder agreed to forbear from enforcing its full remedies related to the Existing Default until the earliest of (i) May 16, 2023, (ii) the occurrence of a default (other than the Existing Default) under the Note or related Note transaction documents, (iii) the Company receives notice from Nasdaq that its compliance plan is not accepted, or the Company’s common stock is delisted or halted from trading for more than one trading day, or (iv) the occurrence of a breach by the Company or its subsidiary of any of the representations, warranties, agreements or covenants. In exchange for the Holder agreeing to enter the Forbearance Agreement, the Company agreed to pay to the Holder a partial acceleration amount of approximately $3.1 million in cash, the restricted amount maintained in a reserve account under the terms of the Note was increased to $1.6 million, and the default interest rate of 18.0% will apply until further notice by the Holder.

Except as set forth above, all other terms, conditions and rights of the Note and the related Note transaction documents remain in full force and effect, which were described in the Current Report on Form 8-K filed by the Company on June 30, 2022, the Quarterly Report on Form 10-Q filed by the Company on November 8, 2022, and the Current Report on Form 8-K filed by the Company on January 13, 2023.

The foregoing description of the Forbearance Agreement does not purport to be complete and is subject to, and qualified by, the full text of such document, a copy of which is filed as Exhibit 10.1 and is incorporated by reference herein.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.Description
Exhibit 10.1
Exhibit 104Cover Page Interactive Data File (embedded within the Inline XBRL document).






SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    
 9 Meters Biopharma, Inc.
    
Date: April 27, 2023By: /s/ Bethany Sensenig
   Bethany Sensenig
   Chief Financial Officer
 
 
 
 

 

 
 
 


EX-10.1 2 ex-101forbearanceagmt423.htm EX-10.1 Document

FORBEARANCE AGREEMENT

THIS FORBEARANCE AGREEMENT (this “Agreement”) dated as of April 26, 2023, is by and among HIGH TRAIL SPECIAL SITUATIONS LLC, a Delaware limited liability company (in its capacity as holder, secured party or collateral agent, as applicable, “Purchaser”), 9 Meters Biopharma, Inc., a Delaware corporation (“Issuer”), and Naia Rare Diseases, LLC, a Delaware limited liability company (“Guarantor” and, together with Issuer, the “Note Parties”).

WITNESSETH:

WHEREAS, the Issuer and Purchaser entered into that certain Securities Purchase Agreement, dated as of June 30, 2022, as amended pursuant to that certain First Amendment to Securities Purchase Agreement, dated as of November 7, 2022 (as further amended, supplemented or otherwise modified from time to time, the “SPA”);
WHEREAS, in connection with the SPA, the Issuer issued in favor of Purchaser that certain Senior Secured Convertible Note due 2025, Certificate No. A-1, which was amended and restated pursuant to that certain Amendment and Restatement of Senior Secured Convertible Note Due 2025, dated as of November 7, 2022, by and between the Issuer and the Purchaser, and further amended as of January 12, 2023, in the original principal amount of $21,000,000 (as further amended, supplemented or otherwise modified from time to time, the “Note”);
WHEREAS, in connection with the SPA and the Note, Guarantor executed and delivered that certain Subsidiary Guaranty, dated as of July 15, 2022 (as amended, supplemented or otherwise modified from time to time, the “Guarantee”), in favor of Purchaser, guaranteeing all obligations of Issuer under the Note and other Note Documents (defined below) as further set forth in the Guarantee;
WHEREAS, in connection with the SPA and the Note, the parties entered into (i) that certain Security Agreement, dated as of July 15, 2022 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Issuer, Guarantor and Purchaser, as secured party and collateral agent, whereby the Note Parties granted security interests in and liens on substantially all personal property of the Note Parties, (ii) that certain Intellectual Property Security Agreement, dated as of July 15, 2022 (as amended, supplemented or otherwise modified from time to time, the “IP Security Agreement” and, together with the SPA, Note, Guarantee, Security Agreement, and all other agreements, documents or instruments ancillary to or executed, delivered or filed in connection with the foregoing, including the Control Agreements (as defined in the Security Agreement) and the other Transaction Documents (as defined in the SPA), the “Note Documents”), among the Issuer, Guarantor and Purchaser, as secured party and collateral agent, whereby the Note Parties granted security interests in and liens on the intellectual property and rights set forth therein.
WHEREAS, on March 31, 2023, Issuer received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1);
WHEREAS, the Events of Default listed on Schedule 1 hereto (the “Existing Defaults”) have occurred and are continuing under the Note Documents;





WHEREAS, the Note Parties have requested that the Purchaser temporarily forbear from enforcing rights or remedies related to the Existing Defaults, except such rights and remedies as are expressly set forth herein, and Purchaser is willing to grant such temporary forbearance, subject to the terms and conditions set forth herein;
NOW, THEREFORE, in consideration of the foregoing premises, and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
AGREEMENT:

1.Recitals. The foregoing recitals are confirmed as true and correct and are incorporated herein by reference. The recitals are a substantive, contractual part of this Agreement.
2.Definitions. Capitalized terms appearing herein and not otherwise defined shall have the meanings ascribed to such terms in the Note Documents, as applicable, unless the context hereof shall otherwise require or provide.
3.Acknowledgements of Note Parties. Each of the Note Parties hereby acknowledges and agrees that: (i) the Existing Defaults have occurred and remain in effect as of the date hereof, (ii) Purchaser has not waived nor agreed to waive such Existing Defaults and has not agreed to any other restructuring, modification, amendment, waiver or forbearance except as expressly set forth herein, (iii) as of the close of business on the date hereof, the outstanding principal balance of the Note is not less than $4,949,522.44, plus accrued and unpaid interest, including Default Interest, of $61,869.03; (iv) because of the Existing Defaults, Purchaser is entitled to exercise all of its rights and remedies as Note holder, secured party and collateral agent, as applicable, under the Note Documents, including, without limitation, by accelerating and declaring the Note due and payable in full immediately for cash in an amount equal to the Event of Default Acceleration Amount pursuant to Section 11(B)(ii) of the Note in the amount of not less than $5,691,950.81, plus accrued and unpaid interest, including Default Interest; (v) the obligations of the Note Parties under the Note Documents include payment of all of Purchaser’s expenses, costs and fees, including attorneys’ fees, actually incurred in the enforcement of the Note Documents and drafting and negotiation of this Agreement.
4.Partial Acceleration. As a result of the Existing Defaults, Purchaser hereby declares a portion of the Note in the principal amount of $2,655,000.00 due and payable immediately in cash (the “Partial Acceleration”) in an amount equal to the Event of Default Acceleration Amount, including accrued and unpaid interest, including Default Interest, of $33,187.50, for an aggregate amount of $3,086,437.50 (the “Partial Acceleration Amount”). Issuer acknowledges that this Agreement constitutes written notice of the Partial Acceleration and waives any requirement under the Note Documents, including under Section 11(B)(ii) of the Note, to receive any other or further notice of same.
5.Reaffirmation and Ratification of Note Documents, Liens and Security Interests. Each of the Note Parties hereby restates, ratifies, and reaffirms all of the terms and provisions of the Note Documents to which it is a party and agrees that such Note Documents are in full force and effect and shall continue to be valid and enforceable, without any

2



counterclaim, defense or setoff, until the obligations are indefeasibly paid in full and all liabilities have been satisfied. Each of the Note Parties hereby restates, ratifies, and reaffirms that all obligations of the Note Parties to the Purchaser are secured by validly perfected, first priority security interests in and liens on substantially all personal property of the Note Parties, as provided in the Security Agreement, IP Security Agreement, Control Agreements, and related Note Documents, and that such liens and security interests are valid and subsisting against the property described in the Note Documents.
6.Forbearance.
(a)Effective upon satisfaction of the conditions set forth in Section 7 below (the “Forbearance Effective Date”), the Purchaser agrees to forbear from the exercise of any further remedies under the Note and the other Note Documents and/or applicable law as a result of the Existing Defaults, for a period (the “Forbearance Period”) beginning on the Forbearance Effective Date through and including the earliest to occur of (i) May 16, 2023, (ii) a Default or Event of Default (other than the Existing Defaults) under the Note Documents, (iii) Issuer receives notice from Nasdaq that its compliance plan is not accepted, or the Common Stock is delisted or halted from trading for more than one Trading Day, or (iv) a breach of any of the representations, warranties, agreements or covenants of any of the Note Parties hereunder (such earliest date, the “Forbearance Termination Date”), unless extended pursuant to a written agreement executed by Purchaser.
(b)Forbearance Limited to Existing Defaults. Purchaser’s forbearance shall be limited solely to the exercise of rights and remedies arising under the Note Documents, applicable law or otherwise as a result of the Existing Defaults, and Purchaser shall not be deemed to have waived any rights or remedies with respect to any other existing or future breach, Default or Event of Default occurring thereunder.
(c)Notice Requirements Satisfied. The Note Parties acknowledge that all notice requirements set forth in the Note Documents and imposed upon Purchaser in connection with the Existing Defaults, and the exercise of its remedies therefor (together with all applicable cure and/or grace periods) have been satisfied (or shall be deemed to have been satisfied by this Agreement) without exception, including, without limitation, notice of the Partial Acceleration pursuant to Section 11(B)(ii) of the Note, and that upon the expiration or earlier termination of the Forbearance Period, Purchaser shall, with respect to the Existing Defaults, have the full right and power to exercise all rights and remedies granted to it thereunder.
7.Conditions of Effectiveness of Forbearance. Purchaser’s agreement to forbear as set forth in Section 6 shall not be effective until the following conditions precedent have been satisfied or waived in writing:
(a)Purchaser shall have received counterparts of this Agreement executed by Issuer and Guarantor;
(b)No Default or Event of Default (other than the Existing Defaults) shall exist;

3



(c)The representations and warranties set forth in the Note Documents and herein shall be true and correct in all material respects, except (i) with respect to the existence of the Existing Defaults, (ii) to the extent already limited by materiality, in which case such representations and warranties shall be true and correct in all respects, and (iii) to the extent such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct as of such earlier date;
(d)The Securities Account of Issuer with Wells Fargo Securities, LLC designated by Account No. [l] shall contain not less than $1,600,000.00;
(e)Purchaser shall have received the Partial Acceleration Amount of $3,086,437.50 by wire transfer in immediately available funds in United States currency to an account designated to Issuer in writing, to be applied by Purchaser to reduce the outstanding principal balance of the Note to $2,294,522.44;
(f)Purchaser shall have received its costs and expenses, including out-of-pocket attorneys’ fees and expenses, in connection with the preparation, negotiation and execution of this Agreement;
(g)The Note Parties shall have made or caused to be made any filing and obtained any consent or authorization as necessary to execute, deliver and perform hereunder; and
(h)Purchaser shall have received such other documents, instruments and certificates as reasonably requested by Purchaser.
8.Representations and Warranties. Each of the Note Parties hereby represents, warrants and certifies that:
(a)The representations and warranties contained in the Note Documents to which it is a party are true and correct in all material respects on and as of the date hereof (except to the extent already limited by materiality, in which case such representations and warranties are true and correct in all respects), except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date;
(b)this Agreement has been duly authorized, executed and delivered and constitutes a legal, valid and binding obligation of such Note Party in accordance with its terms; and
(c)other than the Existing Defaults, no Default or Event of Default exists.
9.Covenants.
(a)Issuer shall deliver a compliance plan to Nasdaq on or before May 15, 2023.

4



(b)Issuer shall provide written notice to the Purchaser promptly upon the occurrence of any event or circumstance that may reasonably be expected to constitute or become a breach or Event of Default.
(c)No later than 9:15 a.m., New York time, on April 27, 2023, Issuer shall file a Current Report on Form 8-K (“Form 8-K”) disclosing all the material terms of the transactions contemplated by this Agreement. From and after the issuance of the Form 8-K, the Issuer and Guarantor shall have disclosed all material, non-public information (if any) provided to Purchaser by the Note Parties or any of their respective subsidiaries or any of their respective officers, directors, employees, or agents, and Purchaser shall not be in possession of any material, non-public information regarding the Issuer, Guarantor or any of their respective subsidiaries.
(d)Issuer shall promptly pay all of Purchaser’s out-of-pocket fees and expenses incurred in connection with the transactions contemplated under this Agreement.
(e)The Note Parties shall take all such actions and execute and deliver all such documents and instruments as requested by Purchaser as necessary to give effect to the terms of this Agreement.
10.Default Rate Matters. Effective as of March 31, 2023, and at all times thereafter until the Issuer is otherwise notified in writing by the Purchaser, the Purchaser is instituting the Default Rate in accordance with Section 4(B)(ii) of the Note. Acceptance of payments tendered by or on behalf of the Note Parties at any time shall not constitute a waiver of the right to receive payment of default interest and other fees, costs and other amounts which are due or become due under the Note Documents and applicable law.
11.Remedies. Upon termination of the Forbearance Period, Purchaser’s agreement to forbear shall terminate automatically without further act or action by Purchaser, and Purchaser shall have the immediate right to exercise its rights and remedies under the Note Documents, hereunder and/or applicable law or in equity, including, without limitation, all rights as a secured creditor under the Uniform Commercial Code and at law and in equity to conduct a foreclosure sale of any portion of the collateral securing the Note.
12.Governing Law and Venue. This Agreement shall in all respects be governed by, and construed in accordance with, the laws of the State of Delaware, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.
13.Headings. Section headings in this Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose.
14.Transaction Document. This Agreement is a Note Document and a Transaction Document (as defined in the SPA) and is subject to all provisions of the Note Documents applicable to Transaction Documents, all of which are incorporated in this Agreement by reference the same as if set forth in this Agreement verbatim.

5



15.Enforceability. Should any one or more of the provisions of this Agreement be determined to be illegal or unenforceable as to one or more of the parties hereto, all other provisions nevertheless shall remain effective and binding on the parties hereto.
16.No Novation. This Agreement is not intended to constitute a novation of the Note or the other Note Documents. All of the indebtedness, liabilities and obligations owing by each of the Note Parties under the Note Documents and liens and security interests granted and perfected thereunder and thereby shall continue to the fullest extent set forth therein.
17.Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of Issuer, Guarantor, Purchaser, and each of their respective successors and permitted assigns, provided that neither Issuer nor Guarantor may, without the prior written consent of Purchaser, assign any rights, powers, duties or obligations hereunder. Purchaser may sell, transfer, or assign any of its rights hereunder or under any of the Note Documents at any time without notice to or consent of Issuer or Guarantor, subject to the provisions of the Note Documents.
18.Waiver and Release. Each of the Note Parties warrants and represents to Purchaser that its obligations under the Note Documents are not subject to any credits, charges, claims, or rights of offset or deduction of any kind or character whatsoever and, as a material part of the consideration for Purchaser entering into this Agreement, each agrees as follows (the “Release Provision”):
(a)EACH OF THE NOTE PARTIES HEREBY RELEASES AND FOREVER DISCHARGES PURCHASER AND ITS PREDECESSORS, SUCCESSORS, ASSIGNS, OFFICERS, MANAGERS, DIRECTORS, MEMBERS, SHAREHOLDERS, EMPLOYEES, AGENTS, ATTORNEYS, REPRESENTATIVES, PARENT CORPORATIONS, SUBSIDIARIES, AND AFFILIATES (HEREINAFTER ALL OF THE ABOVE COLLECTIVELY REFERRED TO AS “RELEASED PARTIES”) JOINTLY AND SEVERALLY FROM ANY AND ALL CLAIMS, COUNTERCLAIMS, DEMANDS, DAMAGES, DEBTS, AGREEMENTS, COVENANTS, SUITS, CONTRACTS, OBLIGATIONS, LIABILITIES, ACCOUNTS, OFFSETS, RIGHTS, ACTIONS, AND CAUSES OF ACTION OF ANY NATURE WHATSOEVER OCCURRING PRIOR TO THE DATE HEREOF, INCLUDING, WITHOUT LIMITATION, ALL CLAIMS, DEMANDS, AND CAUSES OF ACTION FOR CONTRIBUTION AND INDEMNITY, RE-CHARACTERIZATION, OR EQUITABLE SUBORDINATION, WHETHER ARISING AT LAW OR IN EQUITY, PRESENTLY POSSESSED, WHETHER KNOWN OR UNKNOWN, WHETHER LIABILITY BE DIRECT OR INDIRECT, LIQUIDATED OR UNLIQUIDATED, PRESENTLY ACCRUED, WHETHER ABSOLUTE OR CONTINGENT, FORESEEN OR UNFORESEEN, AND WHETHER OR NOT HERETOFORE ASSERTED (“CLAIMS”), WHICH EACH OF THE NOTE PARTIES MAY HAVE OR CLAIM TO HAVE AGAINST ANY OF THE RELEASED PARTIES.
(b)Each of the Note Parties agrees not to sue any of the Released Parties or in any way assist any other Person in suing any of the Released Parties with respect to

6



any Claim released herein. The Release Provision may be pleaded as a full and complete defense to, and may be used as the basis for an injunction against, any action, suit, or other proceeding that may be instituted, prosecuted, or attempted in breach of the release contained herein.
(c)Each of the Note Parties acknowledges, warrants, and represents that it has read and understands the Release Provision and has had the assistance of independent counsel of its own choice in considering the terms of the Release Provision.
19.Returned Proceeds. Anything to the contrary herein notwithstanding, if any proceeds or property are remitted to Purchaser by or on behalf of any of the Note Parties in accordance with the terms hereof, and thereafter, as a result of the exercise of the authority of a trustee or debtor-in-possession under applicable provisions of the U.S. bankruptcy code, other insolvency law, or any provision of applicable federal or state law, Purchaser is required to, and does in fact, remit, rescind or restore the whole or any part of such proceeds or property (the “Returned Proceeds”), (a) the amount of any such Returned Proceeds shall be considered to have been unpaid at all times for the purposes of this Agreement, (b) the obligations of the Note Parties to Purchaser under the Note Documents (less the amount of Returned Proceeds paid and applied on account of the Note and not so returned), and the corresponding lien rights of Purchaser, shall be automatically reinstated nunc pro tunc, and (c) the Note Parties shall indemnify and hold Purchaser harmless from and against any and all losses and reasonable costs and expenses, including reasonable legal fees, incurred by Purchaser arising out of, relating to or in connection with such remittance, recission or restoration.
20.Amendments. This Agreement may not be amended except in a writing executed by Purchaser and all parties hereto.
21.Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original (including electronic copies) but all of which together shall constitute one and the same instrument. Electronic signatures hereto shall be effective as manually executed originals.
[Remainder of page intentionally left blank. Signature pages follow.]



7



IN WITNESS WHEREOF, the Issuer, Purchaser and Guarantor have caused this Agreement to be executed as of the day and year first above written.

ISSUER:

9 METERS BIOPHARMA, INC.,
A Delaware corporation


By:    /s/ Bethany Sensenig        
    Name: Bethany Sensenig    
    Title: Chief Financial Officer


GUARANTOR:

NAIA RARE DISEASES, LLC,
A Delaware limited liability corporation


By:    /s John Temperato        
    Name: John Temperato    
    Title: President



[Signature Page to Forbearance Agreement]


PURCHASER:

HIGH TRAIL SPECIAL SITUATIONS LLC
A Delaware limited liability company


By:    /s/ Eric Helenek        
    Name: Eric Helenek
                         Title: Authorized Signatory

[Signature Page to Forbearance Agreement]



SCHEDULE 1

Existing Defaults

1.An Event of Default has occurred under Section 11(A)(viii) of the Note as a result of the Note or any shares of Common Stock issuable upon conversion of the Note not being Freely Tradable (as defined in the Note).


EX-101.SCH 3 nmtr-20230426.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 nmtr-20230426_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 nmtr-20230426_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, Address Line Two Entity Address, Address Line Two Entity Central Index Key Entity Central Index Key Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Soliciting Material Soliciting Material Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Address Type [Domain] Address Type [Domain] City Area Code City Area Code Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Document Period End Date Document Period End Date Entity Addresses [Line Items] Entity Addresses [Line Items] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Entity Tax Identification Number Entity Tax Identification Number Entity Addresses [Table] Entity Addresses [Table] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Address, City or Town Entity Address, City or Town Former Address Former Address [Member] Local Phone Number Local Phone Number Written Communications Written Communications Cover [Abstract] Document Type Document Type Entity Address, State or Province Entity Address, State or Province Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 6 nmtr-20230426_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
Apr. 26, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Apr. 26, 2023
Entity Registrant Name 9 Meters Biopharma, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-37797
Entity Tax Identification Number 27-3948465
City Area Code 919
Local Phone Number 275-1933
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock $0.0001 Par Value
Trading Symbol NMTR
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001551986
Amendment Flag false
Entity Addresses [Line Items]  
Entity Address, Address Line One 4509 Creedmoor Road
Entity Address, Address Line Two Suite 600
Entity Address, City or Town Raleigh
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27612
Former Address  
Entity Addresses [Line Items]  
Entity Address, Address Line One 4509 Creedmoor Road
Entity Address, Address Line Two Suite 201
Entity Address, City or Town Raleigh
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27612
XML 8 nmtr-20230426_htm.xml IDEA: XBRL DOCUMENT 0001551986 2023-04-26 2023-04-26 0001551986 dei:FormerAddressMember 2023-04-26 2023-04-26 0001551986 false 8-K 2023-04-26 9 Meters Biopharma, Inc. DE 001-37797 27-3948465 4509 Creedmoor Road Suite 600 Raleigh NC 27612 919 275-1933 4509 Creedmoor Road Suite 201 Raleigh NC 27612 false false false false Common Stock $0.0001 Par Value NMTR NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 2 23 1 false 1 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://9meters.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nmtr-20230426.htm ex-101forbearanceagmt423.htm nmtr-20230426.xsd nmtr-20230426_def.xml nmtr-20230426_lab.xml nmtr-20230426_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "nmtr-20230426.htm": { "axisCustom": 0, "axisStandard": 1, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 28 }, "contextCount": 2, "dts": { "definitionLink": { "local": [ "nmtr-20230426_def.xml" ] }, "inline": { "local": [ "nmtr-20230426.htm" ] }, "labelLink": { "local": [ "nmtr-20230426_lab.xml" ] }, "presentationLink": { "local": [ "nmtr-20230426_pre.xml" ] }, "schema": { "local": [ "nmtr-20230426.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 1, "nsprefix": "nmtr", "nsuri": "http://9meters.com/20230426", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nmtr-20230426.htm", "contextRef": "iea721f158a114056b626588622855a2a_D20230426-20230426", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://9meters.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "nmtr-20230426.htm", "contextRef": "iea721f158a114056b626588622855a2a_D20230426-20230426", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]", "terseLabel": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]", "terseLabel": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_FormerAddressMember": { "auth_ref": [ "r6", "r7" ], "lang": { "en-us": { "role": { "documentation": "Former address for entity", "label": "Former Address [Member]", "terseLabel": "Former Address" } } }, "localname": "FormerAddressMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://9meters.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Form 10-Q", "Number": "249", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Form 8-K", "Number": "249", "Publisher": "SEC", "Section": "308", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001551986-23-000028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001551986-23-000028-xbrl.zip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